Pluriomics develops and commercializes fully functional, human iPSC-derived cardiomyocytes and provides high quality services for efficient and reliable safety pharmacology testing and cardiovascular drug efficacy screening.
Pluriomics, a leading expert in human cardiovascular stem cell technology, manufactures fully functional human iPSC derived cardiomyocytes (Pluricyte® Cardiomyocytes) using well-defined, serum-free medium that enhances the maturation and function of the cells. Pluriomics combines Pluricyte® Cardiomyocytes with innovative technologies to develop in-house cell-based assays with the objective to improve drug safety and efficacy screening.
Pluricyte® Cardiomyocytes are fully functional human iPSC derived cardiomyocytes, obtained without genetic modification or purification/selection procedures. The cells possesses a particularly high purity level of >90% based on cardiac Troponin T (TNNT2) expression, of which >70% ventricular, based on the ventricular marker MLC2V. Pluriomics’ proprietary differentiation protocols and well-defined, serum-free medium (Pluricyte® Cardiomyocyte Medium), enables large batch sizes with high reproducibility. Pluricyte® Cardiomyocyte Medium improves the functionality and maturation of Pluricyte® Cardiomyocytes, demonstrated by a high degree of structural sarcomere organization, an increased contraction profile, as well as electrophysiological properties (low membrane potential, increase upstroke velocity and robust sodium spike amplitude) and gene expression patterns comparable to mature cardiomyocytes [Ribeiro et al, 2015].
Due to their relatively high level of purity and maturity, Pluricyte® Cardiomyocytes are exceptionally well-suited for implementation in contractility-, biochemistry- and electrophysiology-based assays. Pluricyte® Cardiomyocyte field potentials show robust and well-pronounced de- and repolarization peaks, which enable easy detection of electrophysiological parameters (e.g. field potential duration) in MEA assays and subsequently efficient analysis and interpretation of data. Application notes describing the use of Pluricyte® Cardiomyocytes in different MEA assays are here available.
“At Pluriomics, we strongly believe that being close to our partners and clients and to provide them with high level support will lead to new and better solutions for efficient decision-making in cardiac safety pharmacology and drug efficacy screening. We are committed to support you from vial to assay outcome and to build a long term relationship.” – S.R. Braam (CEO, Pluriomics)